@article{4776538729af4056b43425307bd6de8c,
title = "Immune Checkpoint Inhibitor–Associated Pericarditis",
abstract = "Side effects of immune checkpoint inhibitors, termed immune-related adverse events, are relatively common, but immune checkpoint inhibitor–mediated cardiotoxicities are rare; however, they can be serious and potentially fatal. Pericarditis is an infrequent cardiac toxicity of immunotherapy and predisposing factors remain unknown. Here we report three patients with NSCLC who developed pericarditis during therapy with programmed death 1/programmed death ligand 1+/- CTLA-4 inhibitors. We review the clinical presentation of these three cases and histopathologic findings from autopsies from the first two patients and a pericardial sampling that has been obtained from a pericardial window procedure in the third patient who recovered from the pericarditis episode. We also discuss the potential mechanisms, as well as what is known about pericarditis secondary to immune-related adverse events.",
keywords = "Immune-related adverse events, NSCLC, Pericarditis",
author = "Mehmet Altan and Toki, {Maria I.} and Gettinger, {Scott N.} and Carvajal-Hausdorf, {Daniel E.} and Jon Zugazagoitia and Sinard, {John H.} and Herbst, {Roy S.} and Rimm, {David L.}",
note = "Funding Information: Disclosure: Dr. Altan has received grants from Bristol-Myers Squibb and Eli Lilly. Dr. Gettinger has received grants from Bristol-Myers Squibb, Nektar Therapeutics, Iovance Biotherapeutics, Genentech, and Takeda/ARIAD; and has received personal fees from Bristol-Myers Squibb and Nektar Therapeutics. Dr Herbst has received honoraria from for following: Consulting: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Heat Biologics, Loxo Oncology, Merck and Company, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Tesaro, Tocagen. Advisory Boards: Neon Therapeutics, Infinity Pharmaceuticals, NextCure. Research support: AstraZeneca, Eli Lilly and Company, Merck and Company. He is a member of the board of directors (non-executive/ independent) for Junshi Pharmaceuticals. Dr. Rimm has received grants from Astra Zeneca, Navigate/Novartis, Cepheid, Perkin Elmer, Ultivue, and Gilead Sciences; and has received personal fees from Bristol-Myers Squibb, Astra Zeneca, Merck, Navigate/Novartis, Agendia, Agilent, Bethyl Labs, Biocept, Cell Signaling Technology, Cepheid, OptraScan, Perkin Elmer, and Ultivue. The remaining authors declare no conflict of interest.This work was supported by funds from the Yale SPORE in Lung Cancer P50-CA196530, the Yale Cancer Center CCSG grant P30-CA016359 and by Stand Up To Cancer - American Cancer Society Lung Cancer Dream Team Translational Research Grant SU2C-AACR-DT17-15. Disclosure: Dr. Altan has received grants from Bristol-Myers Squibb and Eli Lilly. Dr. Gettinger has received grants from Bristol-Myers Squibb, Nektar Therapeutics, Iovance Biotherapeutics, Genentech, and Takeda/ARIAD; and has received personal fees from Bristol-Myers Squibb and Nektar Therapeutics. Dr Herbst has received honoraria from for following: Consulting: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Heat Biologics, Loxo Oncology, Merck and Company, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Tesaro, Tocagen. Advisory Boards: Neon Therapeutics, Infinity Pharmaceuticals, NextCure. Research support: AstraZeneca, Eli Lilly and Company, Merck and Company. He is a member of the board of directors (non-executive/ independent) for Junshi Pharmaceuticals. Dr. Rimm has received grants from Astra Zeneca, Navigate/Novartis, Cepheid, Perkin Elmer, Ultivue, and Gilead Sciences; and has received personal fees from Bristol-Myers Squibb, Astra Zeneca, Merck, Navigate/Novartis, Agendia, Agilent, Bethyl Labs, Biocept, Cell Signaling Technology, Cepheid, OptraScan, Perkin Elmer, and Ultivue. The remaining authors declare no conflict of interest. Funding Information: This work was supported by funds from the Yale SPORE in Lung Cancer P50-CA196530 , the Yale Cancer Center CCSG grant P30-CA016359 and by Stand Up To Cancer - American Cancer Society Lung Cancer Dream Team Translational Research Grant SU2C-AACR-DT17-15. Publisher Copyright: {\textcopyright} 2019 International Association for the Study of Lung Cancer",
year = "2019",
month = jun,
doi = "10.1016/j.jtho.2019.02.026",
language = "English (US)",
volume = "14",
pages = "1102--1108",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",
}